Gilead Stock News

If Gilead has bad news on magrolimab, it could ripple throughout the industry.

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has demonstrated in vitro activity against ten SARS-CoV-2 variants, including omicron.  The study results showed similar activity of Vek

Gilead Sciences Inc''s (NASDAQ: GILD ) Veklury (remdesivir) has demonstrated in vitro activity against ten SARS-CoV-2 variants , including omicron. The study results showed similar activity of Veklury against the variants, and an early ancestral A lineage isolate detected in Seattle, WA (WA1 strain). Specifically, delta and omicron variants both remained fully … Full story available on Benzinga.com

There are some reasons to be optimistic about this drugmaker.

Gilead Sciences'' drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday (Feb 11). The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detec

New data released by Gilead Sciences indicates that its COVID-19 treatment Veklury (remdesivir) is effective against 10 variants, including Omicron.

Shares of Gilead Sciences Inc. gained 0.6% in premarket trading on Friday after the company said Veklury, its COVID-19 drug, demonstrated in-vitro activity against omicron and 9 other variants. The research, which was announced in a news release on Friday morning, was published Thursday as a preprint. Gilead said the study has also been submitted for peer review. "These results provide evidence of the consistent and durable antiviral activity of remdesivir across known variants that have emerged throughout the pandemic, including omicron," Gilead executive Tomas Cihlar said in the release. Veklury generated $5.5 billion in sales in 2022; however, the drug maker said it expects only $2 billion in sales in 2022 if omicron is the only major surge. The treatment has been primarily used in hospitalized COVID-19 patients, but it recently received Food and Drug Administration approval to be used in people who have not yet been hospitalized with COVID-19 but are at high risk of severe disease.

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has demonstrated in vitro activity against ten SARS-CoV-2 variants, including omicron.  The study results showed similar activity of Vekl

There are some reasons to be optimistic about this drugmaker.

Shares of Gilead Sciences Inc. GILD, -2.51% gained 0.6% in premarket trading on Friday after the company said Veklury, its COVID-19 drug, demonstrated in-vitro activity against omicron and 9 other var

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

A whale with a lot of money to spend has taken a noticeably bearish stance on Gilead Sciences . Looking at options history for Gilead Sciences (NASDAQ: GILD ) we detected 19 strange trades. If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 63% with bearish. From the overall spotted trades, 7 are puts, for a total amount of $473,122 and 12, calls, for a total amount of $594,811. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $65.0 for Gilead Sciences over the last 3 months. Volume & Open Interest Development Looking at the volume and open interest is … Full story available on Benzinga.com

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Both offer yields more than twice what the S&P 500 provides.

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.